All In Biotech

Drug Trial Radar · NCT01131546

Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension

A Randomized, Controlled, Multicenter Trial of Levamlodipine Besylate Versus Amlodipine Maleate in Patients With Essential Hypertension

Last checked: Nov 19, 2026Latest source record: Jun 1, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,080 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,080

Planned (sponsor's estimate)

Start

Dec 2009

Primary completion

Mar 2011

Study completion Mar 2011

Sponsor

Sponsor type
Industry
First posted
May 27, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to compare the safety and efficacy of levamlodipine besylate (2.5mg or 5mg) versus amlodipine maleate (5mg) in patients with mild to moderate essential hypertension.

Conditions

  • Essential Hypertension

Interventions

  • Levamlodipine besylateDrug

    Once daily, 7AM - 10AM

  • Amlodipine maleateDrug

    Once daily, 7AM - 10AM

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients who reach overall blood pressure control (defined as BP <140/90 mmHg for non-diabetic patients and < 130/80 mmHg for diabetic patients)Time frame: Week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.